Tag Archive for ‘PBAC’

Press release in response to media reports about the new Gardasil 9 vaccine

Re: ‘New, improved Gardasil 9 fights 90% of cervical cancers, beats genital warts too’ (The Age, September 6, 2017). “A new version of the Gardasil vaccine has been developed and, according to Professor Suzanne Garland, ‘the eradication of cervical cancer is now firmly within our sights.’ Garland is the lead Australian author of a global trial published in The Lancet and funded by the drug’s manufacturer Merck which came to […]

Continue Reading →

“We can now prevent cancer. You can stop your kids getting infected with this cancer-causing virus. It’s staggering,” says expert.

RE: Vaccine could almost eradicate cervical cancer, experts say The lead author and Medical Director of the National HPV Vaccination Program Register, Associate Professor Julia Brotherton is quoted in the Herald Sun: “We can now prevent cancer. You can stop your kids getting infected with this cancer-causing virus. It’s staggering.” Brotherton’s enthusiastic statement comes as The Pharmaceutical Benefits Advisory Committee (PBAC) decides whether to replace the Human Papilloma Virus (HPV) vaccine, Gardasil […]

Continue Reading →

Where’s the debate?

What health official in their right mind is willing to anticipate 2,300 serious adverse events to try and prevent 7.9 cases of cervical cancer? asked Norma Erickson, in her article FDA approved Gardasil 9: Malfeasance or Stupidity? Serious adverse events  are defined as death, life-threatening events, hospitalization, disability or permanent damage. According to information on the Gardasil 9 package insert, for every 100,000 people using Gardasil 9 there would be 2,300 […]

Continue Reading →

Gardasil 9

An application has been made by Seqirus Australia to the Pharmaceutical Benefits Advisory Committee to list Gardasil 9 on the National Immunisation Program as a 2-dose schedule for females and males aged 12-13 years as part of a school age program for the prevention of the human papilloma virus HPV. This listing if approved will replace the current 3-dose schedule of Gardasil, the 4-valent HPV vaccine. The committee whose role […]

Continue Reading →